B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

22.87 +1.36 (+6.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,238,464
Open 22.25
Bid (Size) 22.66 (1)
Ask (Size) 23.25 (1)
Prev. Close 21.51
Today's Range 21.82 - 23.17
52wk Range 19.37 - 39.01
Shares Outstanding 88,140,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings For Intellia Therapeutics
Via Benzinga
3 Gene Editing Stocks with Potential to Transform Medicine
Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. 
Via InvestorPlace

Performance

YTD
-25.79%
-25.79%
1 Month
-16.38%
-16.38%
3 Month
-12.61%
-12.61%
6 Month
-19.67%
-19.67%
1 Year
-39.42%
-39.42%

More News

Read More
NTLA Stock Earnings: Intellia Therapeutics Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
7 Biotech Stocks to Keep on Your Clinical Radar
Via InvestorPlace
3 Gene Editing Stocks That Could Grow Your Wealth
Via InvestorPlace
Unveiling 6 Analyst Insights On Intellia Therapeutics
Via Benzinga
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Via InvestorPlace
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
Via Benzinga
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Via InvestorPlace
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Via The Motley Fool
The 3 Best Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Via InvestorPlace
The 3 Best Biotech Stocks to Buy in July 2024
Via InvestorPlace
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
Via Benzinga
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
Via Benzinga
3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024
Via The Motley Fool
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet
Via InvestorPlace
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
Via InvestorPlace
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
Via Benzinga
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Via Benzinga
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.